Objective: To conduct the first adjuvant trial of imatinib mesylate for treatment of gastrointestinal stromal tumor (GIST). Background: GIST is the most common sarcoma. Although surgical resection has been the mainstay of therapy for localized, primary GIST, postoperative tumor recurrence is common. The KIT protooncogene or, less frequently, platelet-derived growth factor receptor alpha is mutated in GIST; the gene products of both are inhibited by imatinib mesylate. we accrued 106 patients who had undergone complete gross tumor removal but were deemed at high risk for recurrence. Patients were prescribed imatinib 400 mg per day for 1 year and followed with serial radiologic evaluation. The primary endpoint was overall survival (OS). Results: After a median follow-up of 7.7 years, the 1-, 3-, and 5-year OS rates were 99%, 97%, and 83%, which compared favorably with a historical 5-year OS rate of 35%. The 1-, 3-, and 5-year recurrence-free survival (RFS) rates were 96%, 60%, and 40%. On univariable analysis, age and mitotic rate were associated with OS. On multivariable analysis, the RFS rate was lower with increasing tumor size, small bowel site, KIT exon 9 mutation, high mitotic rate, and older age.
I t has now been established that of more than 50 subtypes of sarcoma, gastrointestinal stromal tumor (GIST) is the most common. 1 The annual US incidence is approximately 4000. GIST originates most frequently in the stomach and small intestine, occasionally in the rectum and esophagus, and rarely in the colon or extra-intestinal sites within the abdomen. 2 Surgery has been the standard of care for localized (ie, without metastasis), primary GIST. Historically, despite complete gross tumor resection, as many as 50% of patients eventually died from recurrent disease. 3 Tumor recurrence typically involves the liver or peritoneum. Before the year 2000, there were no effective systemic agents for GIST. 4 In the last 15 years, it was discovered that approximately 85% of GISTs harbor an activating mutation in either the KIT protooncogene (85%) or platelet-derived growth factor receptor alpha (PDGFRA) (3%-5%). 5, 6 Imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland) is a selective inhibitor of KIT and PDGFRA (as well as ABL/BCR-ABL, DDR, and CSF1R) and has become the first line agent for advanced GIST. In patients with metastatic GIST, imatinib has increased the median survival from 9 months to more than 4 years. [7] [8] [9] [10] [11] After the initial results of the B2222 trial for advanced GIST were shared at a National Cancer Institute meeting in December 1999, we designed the American College of Surgeons Oncology Group (ACOSOG) Z9000 trial to assess the efficacy of imatinib in the adjuvant setting for patients at high risk of tumor recurrence. Given that imatinib was effective for metastatic GIST, we hypothesized that adjuvant imatinib would prolong overall survival after the resection of localized, primary GIST in patients at high risk of postoperative tumor recurrence.
METHODS

Patient Eligibility
which included a baseline chest x-ray [or chest computed tomography (CT)] and an abdomen and pelvis CT scan with intravenous and oral contrast, or magnetic resonance imaging with intravenous contrast. Additional inclusion criteria were adequate renal, hematologic, and hepatic function and, when relevant, a negative serum pregnancy test. Patients were excluded if they had been treated postoperatively with imatinib, chemotherapy, radiation therapy, or investigational agents; breast feeding; or taking full dose warfarin. Also excluded were patients with an active infection requiring antibiotics within 14 days before registration or New York Heart Association Class 3 or 4 cardiac disease. The study was approved by the institutional review board of each participating institution, and written informed consent was obtained from all patients.
Study Design and Conduct
Patients were registered within 70 days after complete gross tumor resection and started therapy within 84 days. Imatinib 400 mg per day was prescribed for 1 year. Patients were seen frequently in the first 6 months, every 3 months until year 2, and then every 6 months until year 5 with physical examination and laboratory tests (CBC with differential, creatinine, bilirubin, alkaline phosphatase, and aspartate and alanine aminotransferases). CT scans with intravenous and oral contrast (or magnetic resonance imaging with intravenous contrast) of the abdomen and pelvis were performed every 3 months for the first 2 years and then every 6 months for the following 3 years. Tumor recurrence was determined by clinical impression or biopsy. Patients with tumor recurrence were eligible to resume imatinib 400 mg per day. Drug tolerability was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Attribution was rated as definite, probable, possible, unlikely, or unrelated to the study drug. Dose modifications were made for grade 3 and 4 events (excluding anemia) that were thought to be at least possibly related to treatment. Patients maintained a diary of drug compliance and adverse events. See Figure 1 for CONSORT diagram.
The trial was led by ACOSOG and registered at ClinicalTrials.gov as NCT00025246. It was endorsed by the Southwest Oncology Group (SWOG), Cancer and Leukemia Group B, and Eastern Cooperative Oncology Group, all of which participated through the Cancer Trials Support Unit (CTSU). The trial was conducted via the Cancer Therapy Evaluation Program of the National Cancer Institute and sponsored by Novartis. Novartis employees provided input regarding study design but did not participate in data collection or analysis. Data collected by local institutions were transferred electronically to the ACOSOG central database.
only eligible if their tumors had appropriate microscopic morphology and expressed KIT protein (CD117) by immunohistochemistry. Retrospectively, the mitotic rate was counted by 2 pathologists (C.C. and V.K.) and reported as the number of mitoses per 50 high power fields (totaling 11.87 mm 2 ). Mutational analysis in tumor from consenting patients was performed as described previously. 12
Statistical Analysis
The primary endpoint was to compare overall survival (OS) to that of historical controls. OS was defined as the time from patient registration to death from any cause. On the basis of published data, 5-year OS in high-risk GIST patients was estimated to be 35% with surgery alone. 3, 13 Planned accrual was 89 patients. Adjuvant imatinib was to be considered efficacious in this patient population if 40 or more patients of the first 89 eligible patients enrolled to the trial survived 5 years or longer from trial registration time. This decision criteria and sample size had a level of significance of 0.033 and 86% power to detect an increase in the 5-year survival rate from 35% to 50%. Secondary endpoints included recurrence-free survival (RFS) and patient safety. RFS was defined as the time from patient registration to tumor recurrence or death from any cause. RFS and OS were estimated using the Kaplan-Meier method. Comparisons of RFS and OS between patient subgroups were performed using the log-rank test; a Cox proportional hazards model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI). Multivariable Cox models that adjusted for the high-risk factors of tumor size and tumor location were used for exploratory analyses to identify additional variables that might potentially be prognostic. The database was locked on January 24, 2012, for analysis. All analyses were performed using SAS 9.3 (SAS Institute Inc; Cary, NC).
RESULTS
Patients and Clinicopathologic Features
Between September 2001 and September 2003, 149 patients consented to the protocol. In 13 (8.7%) patients, a diagnosis of GIST could not be confirmed on prospective central pathologic review. Another 27 withdrew or did not meet eligibility criteria. There were a total of 109 patients ( Fig. 1 ) enrolled at 48 institutions (17 via the CTSU). Three patients did not have high-risk GIST and were excluded from the current analysis.
The patient demographics and tumor features are listed in Table 1 . There were more males than females, and the median age was 58 years. The median time to start imatinib therapy was 59 days after surgery. The median tumor size was 13 cm. Of the 106 patients, 85% were eligible based on tumor size, whereas 17% had intra-abdominal tumor rupture before or during surgery and 13% had 4 or less peritoneal metastases. Most (92%) of the tumors originated from the stomach or small intestine. The rate of positive microscopic surgical margins was 10%, similar to that reported previously. 3 About half of tested patients had a high (≥5) mitotic rate.
Adequate tissue for mutation analysis was available in 78 patients. A KIT exon 11 mutation was detected in 58% of tumors. The frequency of a KIT exon 9 mutation was 13%, as was that of a PDGFRA mutation. Meanwhile, 12% of tumors were wild type (ie, lacking a KIT or PDGFRA mutation). There were associations between tumor mutation and mitotic rate, and between tumor mutation and tumor location ( Table 2) . Tumors containing a KIT exon 11 more often had a high mitotic rate, whereas tumors with a PDGFRA mutation nearly always had a low mitotic rate and were located in the stomach. As expected, all tumors with a KIT exon 9 mutation originated in the small intestine. 14 
Safety
Overall, 83% of patients completed the prescribed year of therapy with 69% receiving the prescribed dose ( Fig. 1 ). Dose reductions were necessary in 15%. Therapy was generally well tolerated, consistent with previous experience in GIST patients receiving imatinib for advanced disease or as an adjuvant. 7, 15 The most common adverse events were edema, fatigue, diarrhea, nausea, and dermatitis ( Table 3 ). Grade 1 and 2 events were common, grade 3 events occurred in 26% of patients, and there were no grade 4 or 5 events during therapy. mutation or a wild-type tumor fared better, although these groups were small. Owing to the relatively small number of events, we constructed several exploratory models for multivariable analysis, by including both tumor size and tumor site and then one other variable. By this methodology, KIT exon 9 mutation (HR = 5.11, 95% CI: 1.84-14.14), high mitotic rate (HR = 1.96, 95% CI: 1.01-3.83), and age were each associated with lower RFS (Table 4 ).
Of the first 89 patients enrolled in the trial, 65 (73%) patients survived for 5 or more years, exceeding the a priori criterion [at least 40 (45%) patients surviving at least 5 years] for establishing the efficacy of imatinib in this patient population. The 1-, 3-, and 5-year OS rates based on all 106 eligible patients were 99%, 97%, and 83%, and the median had not been reached (Fig. 3A) . Univariable analysis showed that age and mitotic rate were associated with lower OS (Table 4 ). Patients with a KIT exon 9 mutation tended to have lower OS: their median survival was 54 months versus 103 months for patients with an KIT exon 11 mutation (Fig. 3B) . A multivariable analysis of OS was not performed at this point because of the small number of deaths.
DISCUSSION
This was the first trial ever to test the benefit of adjuvant imatinib for GIST. We defined "high risk" for recurrence by tumor size, tumor rupture, and limited peritoneal disease. Tumor size is known to be associated with outcome in GIST. 12 Certainly, some of the patients in this trial with large tumors would currently be offered neoadjuvant imatinib to facilitate tumor resection. Tumor rupture was previously reported to be associated with a greater than 90% chance of recurrence in a historical series of gastrointestinal "leiomyosarcomas," most of which were probably GISTs. 16 Patients with limited peritoneal metastases from GIST (13% in this series) are now generally treated as having metastatic GIST and so would be excluded from current trial designs of adjuvant therapy. We found that patients with tumor rupture or limited peritoneal metastases did not actually have lower RFS in this trial, perhaps because the entire patient population was at high risk of recurrence anyway. Mitotic rate is the dominant pathologic predictor of outcome in patients with primary GIST treated with surgery alone. 12 However, because of the lack of standardization in measuring mitotic rate, 2 we chose not to include it in the eligibility criteria. Within our high-risk population, we found mitotic rate measured retrospectively to be associated with RFS and OS, but with a much smaller HR than in unselected populations of GIST patients. 12 Since the design of this trial, a number of classification systems [17] [18] [19] have been adopted to assess postoperative risk of recurrence in GIST. The most widely accepted is the Miettinen classification, according to which there were 41 moderate risk patients and 57 high-risk patients in the present series. As expected, patients at high risk by the Miettinen classification had worse outcome, with a median RFS of 36 months and a median OS of 103 months.
Although tumor mutation status is prognostic for survival and predicts the response to imatinib in GIST treatment, none of the current prognostic systems actually include tumor mutation status. We found that patients with a KIT exon 9 mutation had lower RFS than those with either a KIT exon 11 mutation or no detectable mutation. This is consistent with data in metastatic GIST where patients with a KIT exon 9 mutation had worse outcomes compared to patients with a KIT exon 11 mutation. 20, 21 In our primary high-risk patients, the rate of PDGFRA mutation (13%) was much higher than that reported in metastatic GIST, as has been found by others, 22 suggesting that these tumors are less likely to recur. These patients fared relatively well in terms of RFS.
Previously, we reported the results of a large (n = 713 patients), phase 3, placebo-controlled trial testing adjuvant imatinib after the resection of localized, primary GIST at least 3 cm in size. 3 We compared assignment to 1 year of adjuvant imatinib with placebo. After a median follow-up of 19.6 months, the 1-year RFS rate was greater on the imatinib arm (98% vs 83%, P < 0.0002). These results culminated in the approval of adjuvant imatinib for GIST by the Food and Drug Administration in December 2008 and changed the standard of care in many places in the world. Although there is no comparison arm in the present study, we know from the Z9001 trial that in patients with tumors 10 cm or larger, RFS was longer on the imatinib arm than the placebo arm (90% vs 55% at 2 years). As in the Z9001 study, the rate of recurrence in the present trial was minimal during the year of prescribed therapy but markedly increased after 18 months (ie, 6 months after completing the prescribed therapy) following study entry. Longer follow-up in the Z9001 trial should reveal how often imatinib is actually curative. It should be noted in this study that recurrences still occurred after 4 years, which underscores the importance of continued radiologic surveillance.
Although imatinib dramatically increased RFS in ACOSOG Z9001, there was no difference in OS between the arms, possibly due to the modest length of follow-up or the trial design, which permitted crossover to imatinib for patients who developed recurrence on the placebo arm. Longer follow-up is needed to determine whether overall survival is improved by taking imatinib immediately after surgery as opposed to waiting until tumor recurrence. It is noteworthy that in the current study there were just a few deaths within the first 3 years, after which the mortality rate increased considerably. The OS rate was 83% at 5 years, which greatly exceeds historical data and is consistent with the median survival in advanced GIST being 4 years at present. 11 The optimal duration of adjuvant imatinib therapy in GIST is uncertain. Given the increase in the rate of recurrence that developed in both Z9000 and Z9001 patients at approximately 18 months (6 months after the prescribed dose ended), 1 year of therapy seems inadequate, at least if the goal is to maximize RFS. Longer treatment may be indicated in patients with a KIT exon 9 mutation, as this group did not develop recurrence in the first year but did thereafter. It is possible that patients with a KIT exon 9 mutation would do better with higher dose imatinib (eg, 800 mg per day), because this dose seems to delay progression in metastatic GIST. 11 The European Organization for Research and Treatment of Cancer (EORTC) has sponsored an open label, randomized trial (NCT00103168) comparing 0 versus 2 years of adjuvant imatinib in intermediate and high-risk GIST. No data are available at this time. Joensuu and colleagues 23 have recently published data from the Scandinavian Sarcoma Group SSGXVII trial (NCT00116935), in which patients with GIST deemed to be at high risk of recurrence were randomized to 1 or 3 years of adjuvant imatinib and followed for a median of 4.5 years. RFS was greater in patients assigned to 3 years of therapy. OS was also increased but there were relatively few deaths (9% of population); meanwhile, there was no difference in disease-specific survival. Because it was likely that 3 years of therapy would prove superior to 1 year in terms of RFS, we initiated and have already accrued patients to a phase II trial (NCT00867113) of 5 years of adjuvant imatinib for treatment of moderate to high-risk tumors. Thus, the long-term use of adjuvant imatinib may become analogous to chronic hormonal therapy use in breast cancer. At this point, there is general consensus that adjuvant imatinib is not indicated in patients at low risk of tumor recurrence.
CONCLUSIONS
For patients with high-risk GIST, it is clear that 1 year of adjuvant imatinib prolongs OS compared to historical controls. Tumor size, small bowel site, KIT exon 9 mutation, high mitotic rate, and age were associated with RFS, whereas age and mitotic rate correlated with OS. Adjuvant imatinib was well tolerated, as we and others have documented previously. 15, 23 However, discontinuation of therapy coincides with an increased rate of tumor recurrence.
DISCUSSANTS
M. Bertagnolli (Boston, MA):
In 2001, imatinib mesylate was new and there was an incredible amount of excitement about what this drug was able to do in patients with metastatic disease. It took the foresight of surgeons to realize the importance of starting with a high-risk subset of patients with technically resectable disease who could not be randomized because it was not ethical given the nature of what we saw with metastatic disease. However, we understood that these patients needed to be followed, they needed to be studied, and they needed to be more carefully controlled compared with historical controls. This study has much to offer in terms of our understanding of the biology of the disease and where to go next.
Your results are comparable with what has been shown in other trials. Still other studies have expanded upon these results, looking at both 1-and 3-year use of adjuvant imatinib. Data indicate that it probably does not make sense to stop imatinib treatment in patients who have evidence of metastatic disease, such as peritoneal metastasis.
Your mutational analyses data are also consistent with those of other studies; that is, exon 11 mutations are a favorable prognostic factor and also a good marker of response to imatinib. On the contrary, the wild type does not appear to respond to imatinib and probably represents an indolent form of the disease, with exon 9 mutations that are more aggressive.
I have 2 questions that relate to the biology of this disease. First, when do you stop treatment after resection of tumors in patients who have what we now recognize as the highest risk category of disease? When do you stop imatinib treatment, not for the metastatic disease, but for the high-risk resectable disease?
Second, what are your thoughts on what comes next? Our goal is not to give adjuvant chemotherapy only to delay or prolong overall survival. We want to cure these patients. What kind of combination therapy do we use? Do we combine cytotoxic drugs that have been less than effective with the targeted agents?
Response from R.P. DeMatteo (New York, NY):
When to stop therapy is one of the most difficult questions that we face right now if your end point is to prolong recurrence-free survival. In our larger randomized study, we did not see a difference in overall survival between the 2 arms, possibly because we did only a 1-year trial of therapy.
A 1-year versus 3-year trial that followed showed that overall survival is better with 3 years of adjuvant therapy. Yet, in that trial, there were few actual deaths, and disease-specific survival was no different between the 2 groups. Both that recent publication and some work that we are putting together now on our original Z9001 trial show that there is likely not an advantage in overall survival based on length of treatment. Nevertheless, if the goal is to prolong recurrence-free survival, we tend not to stop the therapy. Anticipating that 3 years of treatment was going to produce a better outcome than 1 year, we started a 5-year trial at the same time. We have about 90 patients now in the middle of the 5-year trial, and it will be interesting to see what the recurrence-free survival curve looks like.
Regarding the second question, there was enormous excitement generated around this drug and its potential use for GIST. Of course even though imatinib is the most dramatic example of a targeted molecular agent for any solid cancer to date, there are still many patients dying. As you said, we are not necessarily curing any of these patients. One approach to treatment would be to combine molecular inhibitors. Alternatively, a combination of imatinib with the immune activator ipilimumab has shown promise in a mouse model, which has led to a phase I study sponsored by the National Cancer Institute. It is clear that multimodality therapy will be necessary to cure patients with GIST.
DISCUSSANTS
N. Merchant (Nashville, TN):
I want to reemphasize the importance of this trial and the Z9001 trial that have established the role of imatinib for this tumor. Both of these studies clearly show that longer-term therapy with imatinib is needed, otherwise you are likely just delaying recurrences and, as you say, we have not defined the optimal length of treatment.
More important, this study identifies mutations that we know confer higher risk or lower risk for recurrence; for example, exon 9 mutations are a high-risk factor and perhaps PDGFR mutations are a better prognostic factor. Before we commit these patients to longterm therapy with an expensive drug, we should start substratifying these patients on the basis of their mutational status. For example, perhaps a patient with a 12-cm GIST that has a PDGFR mutation and a low mitotic index may not require therapy because the risk of recurrence is low compared with a patient with a smaller tumor that has an exon 9 mutation who may still require treatment because of the tumor's higher risk of recurrence. Now that we have this type of mutational information, we should start stratifying patients for therapy instead of using a onesize-fits-all approach.
Response from R.P. DeMatteo (New York, NY):
Of course, for many types of tumors-lung, breast, gastrointestinal stromal-we have now identified multiple subcategories. Not long ago, it was remarkable just to diagnose GIST. Now it has become apparent that there are GIST subtypes with different biologic behaviors.
To try to stratify patients for risk of recurrence, we created a nomogram, available online, that estimates the risk of recurrence for an individual patient, which is useful in discussing treatment options with patients.
We started by treating everyone with a GIST of at least a couple of centimeters in size; that is now not necessary. We can take half the patients out of consideration for adjuvant therapy just by using the nomogram and other risk stratification systems, such as, Miettinen's. For the other half of patients with certain mutations, adjuvant therapy does not necessarily confer an advantage. For instance, we can exclude patients with wild type tumors or the imatinib-resistant PDGFRA D842V mutation.
DISCUSSANTS
D.W. Mcfadden (Farmington, CT):
What are your thoughts about neoadjuvant imatinib? Are there other trials planned for that?
Response from R.P. DeMatteo (New York, NY):
We could not use the neoadjuvant approach in this trial because the drug had not yet been approved and so was not available outside of any trial. There is no question that for many, the patients in this study would now be eligible for a 3-to 6-month trial of neoadjuvant therapy. The main reason to use neoadjuvant therapy is to try to reduce the extent of surgery. In particular, for stomach tumors, we can often avoid total gastrectomy. The other advantage of giving neoadjuvant therapy is that the tumors are considerably less vascular, which makes the operation much easier.
Most of the benefit in terms of shrinkage happens by 6 months, so our current routine is to use neoadjuvant therapy for large tumors that are situated in difficult locations.
